Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Curr Opin Virol. 2019 Feb 10;35:1–13. doi: 10.1016/j.coviro.2018.12.009

Table 1.

Host-directed anti-RABV compounds

Compound Target EC50 (uM) CC50 (uM) SI (CC50/EC50) Ref.
Catechin Host Cell GAGs 36.50 ± 8.40 124.33 ± 33.53 3 [54, 63]
Quercetin Host Cell GAGs 191.68 ± 24.25 670.02 ± 180.18 3 [54, 63]
3,4,5-Trimethoxybenzoic acid Host Cell GAGs 2142.74 ± 266.37 >5042.41 2 [54, 63]
Trimethoxyacetophenone Host Cell GAGs 1023.98 ± 64.62 3738.98 ± 1099.17 3 [54, 63]
3,4,5-Trimethoxybenzoic acid ethyl ester Host Cell GAGs 822.23 ± 134.38 3204.20 ± 397.87 3 [54, 63]
Butyl gallate Host Cell GAGs 109.79 113.23 ± 52.35 1 [54, 63]
PAV-866 ABCE1 ~0.15–0.30 ~2.5–10 ~100 [55]
Sorafenib Tyrosine Kinases 1.463 >160 109 [22]
2-piperidin-3-yl-benzothiazole analog Nedd4 0.345 >1 >3 [126]
1-acetyl-3-(2,2,2-trifluoroethyl)-urea analog Nedd4 0.210 >1 >8 [126]